Minodronic acid

Not to be confused with mildronate or medronate.

Minodronic acid
Names

IUPAC name (1-Hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid
Other names Minodronate; YM 529
Identifiers
CAS Number	180064-38-4^N 155648-60-5 (hydrate)^Y
3D model (Jmol)	Interactive image
ChEMBL	ChEMBL319144^Y
ChemSpider	115805^Y
IUPHAR/BPS	3164
PubChem	130956
UNII	40SGR63TGL^N
InChI InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)^Y Key: VMMKGHQPQIEGSQ-UHFFFAOYSA-N^Y
SMILES O=P(O)(O)C(O)(P(=O)(O)O)Cc1cnc2ccccn12
Properties
Chemical formula	C₉H₁₂N₂O₇P₂
Molar mass	322.15 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is ^YN ?)
Infobox references

Minodronic acid is a third-generation bisphosphonate drug. It is approved for use in Japan for the treatment of osteoporosis.^[1] Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity.^[2]

References

↑ Shridhar Hegde and Michelle Schmidt (2009). "To Market, To Market - 2009. 16. Minodronic acid". Annual Reports in Medicinal Chemistry. 45: 509–510. doi:10.1016/s0065-7743(10)45028-9.
↑ Sorbera, L.A.; Castañer, J.; Leeson, P.A. (2002). "Minodronic Acid". Drugs of the Future. 27 (10): 935–941. doi:10.1358/dof.2002.027.10.701186.

This article is issued from Wikipedia - version of the 3/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.